The New Healthcare Reality Under the Trump Administration
Jeffrey Casberg, M.S., of IPD Analytics and Luke Greenwalt, MBA, of IQVIA, both members of the Managed Healthcare Executive (MHE) editorial advisory board, will provide a midyear assessment of the pharmacy market and the policy and politics affecting it. Topics to be discussed include the possibility of tariffs, the most-favored nation drug pricing executive order, aspect of the reconciliation bill that could affect the pharmaceutical and pharmacy benefit management industries, pressure on the gross-to-net “bubble,” implementation of the Inflation Reduction Act price negotiations, GLP-1s and notable FDA approvals in the second half of 2025. Note that this a menu and some topics may be added or subtracted depending on time and news up to airtime on June 12. Peter Wehrwein, managing editor of MHE is moderating the discussion.
